Page 8 - Edwards Higher Standard Brochure PP--US-5551 v3.0
P. 8

Only SAPIEN 3 TAVR is proven superior to surgery in low-risk patients PARTNER 3 Low-Risk Trial
Benefit of TAVR sustained at 2 years*3
  Primary endpoint:
Death, stroke, rehospitalization at 1 year1
TAVR
Surgery
 8.5%
 15.1%
    Death or disabling stroke1
10
5
P=0.03
2.9% surgery
1.0% SAPIEN 3 TAVR
12 1%
  1.3%
   Number at Risk
Surgery
SAPIEN 3 TAVR
00.4% 3 6 9 Months after procedure
454 444 436 432 430
496 494 494 493 491
426
488
death or disabling stroke at 1 year1
  * More death and stroke events in TAVR patients from 1 to 2 years; no significant differences at 2 years
 Percent of patients








































































   6   7   8   9   10